adalimumab-afzb (Abrilada) vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
etanercept · Enbrel
Marketed by Amgen and partners
NCT00317499 · Phase 3 · completed
Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and week 24): ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) (met)
Result source: NCT02376790
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | etanercept |
|---|---|---|
| ACR20 | —Not reported | 60.9% vs 50.7%vs MethotrexateNCT0237679015 other results
|
| ACR50 | —Not reported | 63% vs 49.3%vs MethotrexateNCT0237679013 other results
|
| PASI 75 | —Not reported | —Not posted · NCT00317499 |
| Minimal disease activity | —Not reported | 51.3% vs 35.8%vs MethotrexateNCT0237679013 other results
|
| HAQ-DI, change | —Not reported | -0.6 vs -0.5vs MethotrexateNCT0237679015 other results
|
ACR20
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 60.9% vs 50.7%vs MethotrexateNCT02376790
15 other results
- 65% vs 50.7% NCT02376790
- 83.1% vs 70.7% NCT02376790
- 80.4% vs 70.7% NCT02376790
- 77% vs 66.3% NCT02376790
- 74.2% vs 66.3% NCT02376790
- 67.6% vs 56.9% NCT02376790
- 71.9% vs 56.9% NCT02376790
- 69.5% vs 58.5% NCT02376790
- 71.8% vs 58.5% NCT02376790
- 65.5% vs 46.8% NCT02376790
- 70.3% vs 46.8% NCT02376790
- 60.2% vs 46.5% NCT02376790
- 60.8% vs 46.5% NCT02376790
- 44.3% vs 25% NCT02376790
- 46.4% vs 25% NCT02376790
ACR50
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 63% vs 49.3%vs MethotrexateNCT02376790
13 other results
- 60.2% vs 49.3% NCT02376790
- 57.3% vs 41.8% NCT02376790
- 56% vs 41.8% NCT02376790
- 44.4% vs 30.6% NCT02376790
- 45.7% vs 30.6% NCT02376790
- 43.8% vs 29.2% NCT02376790
- 43.4% vs 29.2% NCT02376790
- 40.4% vs 16.9% NCT02376790
- 39.2% vs 16.9% NCT02376790
- 31.3% vs 15.1% NCT02376790
- 30.1% vs 15.1% NCT02376790
- 16.5% vs 6% NCT02376790
- 18.8% vs 6% NCT02376790
PASI 75
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- —Not posted · NCT00317499
Minimal disease activity
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 51.3% vs 35.8%vs MethotrexateNCT02376790
13 other results
- 53.2% vs 35.8% NCT02376790
- 43.5% vs 30.3% NCT02376790
- 46.7% vs 30.3% NCT02376790
- 35.9% vs 22.9% NCT02376790
- 35.7% vs 22.9% NCT02376790
- 39.5% vs 25.7% NCT02376790
- 39.1% vs 25.7% NCT02376790
- 29.9% vs 11.6% NCT02376790
- 29.1% vs 11.6% NCT02376790
- 9.4% vs 3% NCT02376790
- 7.4% vs 3% NCT02376790
- 11.1% vs 5.7% NCT02376790
- 12.6% vs 5.7% NCT02376790
HAQ-DI, change
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- -0.6 vs -0.5vs MethotrexateNCT02376790
15 other results
- -0.6 vs -0.5 NCT02376790
- -0.5 vs -0.5 NCT02376790
- -0.5 vs -0.5 NCT02376790
- -0.4 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.4 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.5 vs -0.4 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.5 vs -0.3 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.4 vs -0.3 NCT02376790
- -0.3 vs -0.2 NCT02376790
- -0.3 vs -0.2 NCT02376790
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-afzb (Abrilada): no structured comparison results are available for Psoriatic Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-afzb (Abrilada): 0 of 4 rows · etanercept: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | etanercept |
|---|---|
| Dropout rate | 18.7%Etanercept + Methotrexatea NCT02376790 · Phase 3 · combination show 5 more results16.5%Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 35.5% NCT00127842 · Phase 4 · registry result, not featured evidence 4%BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 2.9%QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence — NCT02986139 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —Etanercept + Methotrexatea NCT02376790 · Phase 3 · combination show 5 more results—Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 13.6% NCT00127842 · Phase 4 · registry result, not featured evidence 1.6%BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 1.9%QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence — NCT02986139 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 6%Etanercept + Methotrexatea NCT02376790 · Phase 3 · combination show 5 more results6.7%Etanercept Monotherapy NCT02376790 · Phase 3 · monotherapy 12.7% NCT00127842 · Phase 4 · registry result, not featured evidence —BIW/QW NCT00245960 · Phase 4 · registry result, not featured evidence —QW/QW NCT00245960 · Phase 4 · registry result, not featured evidence 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 14.4% nasopharyngitis 9.5% upper respiratory tract infection 8.1% NCT02376790 · Phase 3 · combination show 5 more resultsnasopharyngitis 7.4% nausea 6.4% upper respiratory tract infection 6.4% NCT02376790 · Phase 3 · monotherapy nasopharyngitis 18.2% upper respiratory tract infection 13.6% injection site reaction 11.8% NCT00127842 · Phase 4 · registry result, not featured evidence BIW/QW upper respiratory infection 13.2% skin and appendages general disorders 11.9% digestive general disorders 10% NCT00245960 · Phase 4 · registry result, not featured evidence QW/QW skin and appendages general disorders 11% digestive general disorders 9.9% upper respiratory infection 9.7% NCT00245960 · Phase 4 · registry result, not featured evidence hypoaesthesia 1.9% pain in extremity 1.9% cellulitis 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etanercept
show 15 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 13 more results
show 15 more results
show 13 more results
show 7 more results
+ 23 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
etanercept · Enbrel
Marketed by Amgen and partners
NCT00111436 · Phase 3 · completed
Participants in this study had already been randomized in an earlier controlled trial and continued on etanercept here as an open-label extension to gather longer-term safety data, rather than as a fresh randomized comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Subject incidence of adverse events, including infectious episodes" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Subject incidence of adverse events, including infectious episodes (72 weeks); Changes from baseline in laboratory values (72 weeks): Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases. (not_applicable)
Result source: NCT00111436
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | etanercept |
|---|---|---|
| PASI 75 | —Not reported | 57% vs 11%+46 vs placeboNCT000788192 other results
|
| PASI 90 | —Not reported | 27% vs 7%+20 vs placeboNCT00078819 |
| PASI 100 | —Not reported | —Not posted · NCT00111449 |
| sPGA 0/1 | —Not reported | 28.9% vs 3.6%+25.3 vs placeboNCT016902992 other results
|
| DLQI, change | —Not reported | -7.8 vs -3.9−3.9 vs placeboNCT01690299 |
PASI 75
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 57% vs 11%+46 vs placeboNCT00078819
2 other results
- 48.2% vs 11.9% NCT01690299
- 63.3% vs 26.3% NCT03073200
PASI 90
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 27% vs 7%+20 vs placeboNCT00078819
PASI 100
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- —Not posted · NCT00111449
sPGA 0/1
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 28.9% vs 3.6%+25.3 vs placeboNCT01690299
2 other results
- 53% vs 13% NCT00078819
- 53.3% vs 5.3% NCT03073200
DLQI, change
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- -7.8 vs -3.9−3.9 vs placeboNCT01690299
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-afzb (Abrilada): no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-afzb (Abrilada): 0 of 4 rows · etanercept: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | etanercept |
|---|---|
| Dropout rate | —0.8 mg/kg QWa NCT00078819 · Phase 3 show 35 more results—0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 0.9%Etanercept NCT00078819 · Phase 3 17.5% NCT02749370 · Phase 4 · registry result, not featured evidence 16% NCT01971346 · Phase 4 · registry result, not featured evidence 18.9% NCT02274792 · Phase 4 · registry result, not featured evidence 16.3% NCT00992394 · Phase 4 · registry result, not featured evidence 0% NCT01053819 · Phase 4 · registry result, not featured evidence 5.1%Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 6.5%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 27.6% NCT00332332 · Phase 4 · registry result, not featured evidence 8.8%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 7.3%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 34.5% NCT00581555 · Phase 4 · registry result, not featured evidence 14.7%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 18.4%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 27.7%Continuous NCT00195507 · Phase 4 · registry result, not featured evidence 32.5%Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence 0% NCT03073200 · Phase 3 · registry result, not featured evidence 77.5% NCT00141921 · Phase 3 · registry result, not featured evidence 2.4%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 5.6%50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination —Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 14.9%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 14.8%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 7.2%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 9.3%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 0%50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence 33.3% NCT01170715 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —0.8 mg/kg QWa NCT00078819 · Phase 3 show 35 more results—0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 —0.8 mg/kg QW NCT00078819 · Phase 3 0.9%Etanercept NCT00078819 · Phase 3 — NCT02749370 · Phase 4 · registry result, not featured evidence — NCT01971346 · Phase 4 · registry result, not featured evidence — NCT02274792 · Phase 4 · registry result, not featured evidence 5.8% NCT00992394 · Phase 4 · registry result, not featured evidence — NCT01053819 · Phase 4 · registry result, not featured evidence —Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence —Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 1.6%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 5.3% NCT00332332 · Phase 4 · registry result, not featured evidence 4.4%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 2.2%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 5.2% NCT00581555 · Phase 4 · registry result, not featured evidence 2.9%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 5.3%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 6.7%Continuous NCT00195507 · Phase 4 · registry result, not featured evidence 3.6%Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence — NCT03073200 · Phase 3 · registry result, not featured evidence 2.7% NCT00141921 · Phase 3 · registry result, not featured evidence 1.2%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 0%50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination —Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 2%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 1.3%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 2.4%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 6.5%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence —50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence — NCT01170715 · Phase na · registry result, not featured evidence |
| Serious AEs | 0%0.8 mg/kg QWa NCT00078819 · Phase 3 show 35 more results0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 0%0.8 mg/kg QW NCT00078819 · Phase 3 —Etanercept NCT00078819 · Phase 3 2.5% NCT02749370 · Phase 4 · registry result, not featured evidence 2.2% NCT01971346 · Phase 4 · registry result, not featured evidence 3.8% NCT02274792 · Phase 4 · registry result, not featured evidence 4.8% NCT00992394 · Phase 4 · registry result, not featured evidence 0% NCT01053819 · Phase 4 · registry result, not featured evidence 1%Part 1 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence 5.3%Part 2 - Etanercept NCT00640393 · Phase 4 · registry result, not featured evidence 0%Part 2 - Etanercept and nbUVB NCT00640393 · Phase 4 · registry result, not featured evidence · combination 3.4%50 mg BIW/QW NCT00791765 · Phase 4 · registry result, not featured evidence 5.2% NCT00332332 · Phase 4 · registry result, not featured evidence 2.2%50 mg BW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 2.9%50 mg QW/QW NCT00663052 · Phase 4 · registry result, not featured evidence 3.4% NCT00581555 · Phase 4 · registry result, not featured evidence 0%Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence 5.3%Twice, Then Once Weekly NCT00581100 · Phase 4 · registry result, not featured evidence —Continuous NCT00195507 · Phase 4 · registry result, not featured evidence —Intermittent NCT00195507 · Phase 4 · registry result, not featured evidence 3.3% NCT03073200 · Phase 3 · registry result, not featured evidence 3.9% NCT00141921 · Phase 3 · registry result, not featured evidence —50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence 2.4%50 mg SC QW NCT01690299 · Phase 3 · registry result, not featured evidence —50 mg QW + topical NCT01313221 · Phase 3 · registry result, not featured evidence · combination 2.3%Etanercept Monotherapy NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy 2.4%Etanercept + Clobetasol Propionate NCT01235442 · Phase 3 · registry result, not featured evidence · combination 2%Etanercept Monotherapy NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 2.9%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 2.4%50 mg NCT00482170 · Phase 3 · registry result, not featured evidence 0%50 mg twice weekly NCT00585650 · Phase 1/2 · registry result, not featured evidence 9.5% NCT01170715 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 0.8 mg/kg QWa upper respiratory tract infection 12.5% (placebo 11.4%) skin papilloma 6.3% (placebo 0%) acne 3.1% (placebo 0%) NCT00078819 · Phase 3 show 31 more results0.8 mg/kg QW upper respiratory tract infection 17% (placebo 11.4%) headache 13.2% (placebo 12.4%) influenza 7.5% (placebo 1.9%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 42.4% (placebo 11.4%) headache 20.3% (placebo 12.4%) nasopharyngitis 20.3% (placebo 8.6%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 30.8% (placebo 11.4%) headache 20.2% (placebo 12.4%) nasopharyngitis 18.8% (placebo 8.6%) NCT00078819 · Phase 3 0.8 mg/kg QW upper respiratory tract infection 25% (placebo 11.4%) abdominal pain 8.3% (placebo 0%) body tinea 8.3% (placebo 0%) NCT00078819 · Phase 3 0.8 mg/kg QW nasopharyngitis 10.3% (placebo 8.6%) headache 8.8% (placebo 12.4%) acne 2.9% (placebo 0%) NCT00078819 · Phase 3 back pain 2.5% exostosis 2.5% injection related reaction 2.5% NCT02749370 · Phase 4 · registry result, not featured evidence nasal congestion 8.7% gi distress 6.5% injection site reaction 6.5% NCT01971346 · Phase 4 · registry result, not featured evidence injection site reaction 7.6% psoriasis 6.1% headache 5.3% NCT02274792 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.2% bronchitis 10.7% arthralgia 7.1% NCT00992394 · Phase 4 · registry result, not featured evidence common cold 9.1% injection site reaction 4% upper respiratory tract infection 4% NCT00640393 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 15.8% common cold 13.2% injection site reaction 0% NCT00640393 · Phase 4 · registry result, not featured evidence common cold 5.4% upper respiratory tract infection 2.7% injection site reaction 0% NCT00640393 · Phase 4 · registry result, not featured evidence · combination 50 mg BIW/QW nasopharyngitis 8.5% (placebo 8.1%) upper respiratory tract infection 8.5% (placebo 14.5%) arthralgia 6.8% (placebo 3.2%) NCT00791765 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.8% headache 7% upper respiratory tract infection 7% NCT00332332 · Phase 4 · registry result, not featured evidence 50 mg BW/QW headache 11% nasopharyngitis 10.3% upper respiratory tract infection 6.6% NCT00663052 · Phase 4 · registry result, not featured evidence 50 mg QW/QW nasopharyngitis 16.1% headache 10.9% diarrhoea 7.3% NCT00663052 · Phase 4 · registry result, not featured evidence headache 29.3% (placebo 33.9%) nasopharyngitis 19% (placebo 21%) hypertension 15.5% (placebo 14.5%) NCT00581555 · Phase 4 · registry result, not featured evidence Once Weekly nasopharyngitis 11.8% headache nos 8.8% alopecia areata 2.9% NCT00581100 · Phase 4 · registry result, not featured evidence Twice, Then Once Weekly headache nos 10.5% nasopharyngitis 10.5% dermatitis allergic 5.3% NCT00581100 · Phase 4 · registry result, not featured evidence upper respiratory infection 17.9% headache 17.6% nervous 13.4% NCT00195507 · Phase 4 · registry result, not featured evidence upper respiratory infection 17.4% headache 12.9% arthralgia 11% NCT00195507 · Phase 4 · registry result, not featured evidence influenza 6.7% (placebo 0%) pharyngitis 6.7% (placebo 0%) bronchitis 3.3% (placebo 0%) NCT03073200 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 37.6% nasopharyngitis 26% headache 21.5% NCT00141921 · Phase 3 · registry result, not featured evidence 50 mg SC QW nasopharyngitis 9.6% (placebo 9.5%) headache 6% (placebo 3.6%) cough 4.8% (placebo 3.6%) NCT01690299 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.6% headache 10.7% injection site reaction 9% NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy nasopharyngitis 8.3% upper respiratory tract infection 6.9% sinusitis 6.3% NCT01235442 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 11.6% nasopharyngitis 8.6% headache 7.3% NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy 50 mg nasopharyngitis 11.6% injection site reaction 8.7% headache 6.3% NCT00482170 · Phase 3 · registry result, not featured evidence 50 mg nasopharyngitis 12.8% injection site erythema 8.1% injection site reaction 8.1% NCT00482170 · Phase 3 · registry result, not featured evidence 50 mg twice weekly upper respiratory infection 37.5% (placebo 33.3%) NCT00585650 · Phase 1/2 · registry result, not featured evidence upper respiratory infection 28.6% fatigue 9.5% rash 9.5% NCT01170715 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etanercept
show 2 more results
show 1 more result
show 2 more results
show 52 more results
show 29 more results
show 43 more results
show 12 more results
show 45 more results
show 5 more results
show 5 more results
+ 51 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-afzb (Abrilada)
Marketed by Pfizer
NCT02480153 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)
Result source: NCT02480153
etanercept · Enbrel
Marketed by Amgen and partners
NCT03780959 · Phase 2/3 · completed
After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% (met)
Result source: NCT03780959
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-afzb (Abrilada) | etanercept |
|---|---|---|
| ACR20 | 68.3% vs 71.3%vs Adalimumab-EUNCT0248015311 other results
| 78.6% vs 62.5%vs MethotrexateNCT0044577063 other results
|
| ACR50 | 62.9% vs 55.6%vs Adalimumab-EUNCT0248015311 other results
| 62.1% vs 36.9%vs MethotrexateNCT0044577065 other results
|
| ACR70 | 36.4% vs 31.9%vs Adalimumab-EUNCT0248015311 other results
| 36.3% vs 15.9%vs MethotrexateNCT0044577064 other results
|
| DAS28-CRP remission | —Not reported | 54.5% vs 69.1%vs Standard COBRA-Slim InductionNCT036490611 other result
|
| HAQ-DI, change | -0.7 vs -0.7vs Adalimumab-EUNCT0248015311 other results
| -0.6 vs -0.3vs MethotrexateNCT0044577031 other results
|
| Modified Sharp score, change | —Not reported | 3.3 vs 9.8vs MethotrexateNCT0044577011 other results
|
ACR20
- adalimumab-afzb (Abrilada)
- 68.3% vs 71.3%vs Adalimumab-EUNCT02480153
11 other results
- 82.7% vs 79.3% NCT02480153
- 82.3% vs 78.5% NCT02480153
- 83.4% vs 77.8% NCT02480153
- 86.6% vs 82.2% NCT02480153
- 83.5% vs 78% NCT02480153
- 86.6% vs 84.4% NCT02480153
- 78.1% vs 73.7% NCT02480153
- 69.4% vs 68% NCT02480153
- 61.3% vs 59.7% NCT02480153
- 51.9% vs 52.3% NCT02480153
- 31.3% vs 32% NCT02480153
- etanercept
- 78.6% vs 62.5%vs MethotrexateNCT00445770
63 other results
- 79.7% vs 59.1% NCT00445770
- 75.3% vs 59.7% NCT00445770
- 80.8% vs 58% NCT00445770
- 77.5% vs 56.3% NCT00445770
- 78.6% vs 58.5% NCT00445770
- 75.3% vs 51.7% NCT00445770
- 77.5% vs 48.3% NCT00445770
- 68.7% vs 43.2% NCT00445770
- 56.9% vs 27.3% NCT00445770
- 49.4% vs 16.1% NCT00445770
- 75.9% vs 62.5% NCT00445770
- 76.4% vs 59.1% NCT00445770
- 78.5% vs 59.7% NCT00445770
- 79.1% vs 58% NCT00445770
- 77% vs 56.3% NCT00445770
- 75.4% vs 58.5% NCT00445770
- 73.8% vs 51.7% NCT00445770
- 70.2% vs 48.3% NCT00445770
- 68.1% vs 43.2% NCT00445770
- 55.5% vs 27.3% NCT00445770
- 54% vs 16.1% NCT00445770
- 77% vs 50.3% NCT00565409
- 75% vs 50.3% NCT00565409
- 76.9% vs 61.2% NCT00565409
- 76.5% vs 48.7% NCT00565409
- 86.5% vs 88.3% NCT00565409
- 78% vs 47.2% NCT00565409
- 79.5% vs 46.7% NCT00565409
- 75.5% vs 48.7% NCT00565409
- 76.1% vs 50.3% NCT00565409
- 74.6% vs 50.3% NCT00565409
- 77.7% vs 61.2% NCT00565409
- 74.1% vs 48.7% NCT00565409
- 85.1% vs 88.3% NCT00565409
- 74.6% vs 47.2% NCT00565409
- 77.6% vs 46.7% NCT00565409
- 74.6% vs 48.7% NCT00565409
- 96.8% vs 98.5% NCT00913458
- 93.7% vs 86.2% NCT00913458
- 96.8% vs 67.7% NCT00913458
- 90.5% vs 61.5% NCT00913458
- 51.9% vs 54.8% NCT01313208
- 49.1% vs 47.1% NCT01313208
- 87.3% vs 47.7% NCT00913458
- 40.6% vs 28.8% NCT01313208
- 50% vs 23.1% NCT01313208
- 36.8% vs 19.2% NCT01313208
- 28.6% vs 14.9% NCT01313208
- 90% vs 86.5% NCT00848354
- 88.8% vs 91.3% NCT00848354
- 86.9% vs 81.0% NCT00848354
- 89.2% vs 87.3% NCT00848354
- 83.2% vs 50% NCT00848354
- 84.6% vs 58.5% NCT00848354
- 84.2% vs 57.8% NCT00848354
- 90.9% vs 89.2% NCT00848354
- 79.6% vs 54.9% NCT00848354
- 73.8% vs 49.3% NCT00848354
- 63.8% vs 34.5% NCT00848354
- 47.8% vs 19.3% NCT00848354
- 91.7% vs 90.8% NCT00848354
- 90.0% vs 83.3% NCT00848354
- 89.2% vs 89.2% NCT00848354
ACR50
- adalimumab-afzb (Abrilada)
- 62.9% vs 55.6%vs Adalimumab-EUNCT02480153
11 other results
- 64.3% vs 49.6% NCT02480153
- 61.1% vs 51.9% NCT02480153
- 59.7% vs 49.6% NCT02480153
- 59.6% vs 54.7% NCT02480153
- 61.8% vs 56.3% NCT02480153
- 45.1% vs 47% NCT02480153
- 39.7% vs 39.7% NCT02480153
- 34% vs 33.3% NCT02480153
- 27.6% vs 27.3% NCT02480153
- 17.8% vs 14.3% NCT02480153
- 8.4% vs 6% NCT02480153
- etanercept
- 62.1% vs 36.9%vs MethotrexateNCT00445770
65 other results
- 57.7% vs 39.2% NCT00445770
- 58.8% vs 36.9% NCT00445770
- 59.3% vs 34.7% NCT00445770
- 54.4% vs 32.4% NCT00445770
- 50.5% vs 30.7% NCT00445770
- 44% vs 26.1% NCT00445770
- 42.3% vs 23.9% NCT00445770
- 35.7% vs 15.3% NCT00445770
- 22.5% vs 4% NCT00445770
- 16% vs 2.3% NCT00445770
- 59.4% vs 36.9% NCT00445770
- 57.3% vs 39.2% NCT00445770
- 60.4% vs 36.9% NCT00445770
- 60.4% vs 34.7% NCT00445770
- 53.6% vs 32.4% NCT00445770
- 50% vs 30.7% NCT00445770
- 50% vs 26.1% NCT00445770
- 47.4% vs 23.9% NCT00445770
- 38.5% vs 15.3% NCT00445770
- 28.1% vs 4% NCT00445770
- 14.7% vs 2.3% NCT00445770
- 62.0% vs 23.2% NCT00848354
- 58% vs 33.5% NCT00565409
- 62% vs 28.9% NCT00565409
- 60.5% vs 41% NCT00565409
- 59% vs 27.9% NCT00565409
- 76.5% vs 74.1% NCT00565409
- 63% vs 26.9% NCT00565409
- 62.5% vs 27.4% NCT00565409
- 62.5% vs 25.9% NCT00565409
- 59.2% vs 33.5% NCT00565409
- 56.2% vs 28.9% NCT00565409
- 57.9% vs 41% NCT00565409
- 55.7% vs 27.9% NCT00565409
- 70.6% vs 74.1% NCT00565409
- 53.7% vs 26.9% NCT00565409
- 58.7% vs 27.4% NCT00565409
- 57.2% vs 25.9% NCT00565409
- 92.1% vs 95.4% NCT00913458
- 87.3% vs 73.8% NCT00913458
- 93.7% vs 50.8% NCT00913458
- 85.7% vs 50.8% NCT00913458
- 33% vs 28.8% NCT01313208
- 29.2% vs 28.8% NCT01313208
- 30.2% vs 22.1% NCT01313208
- 76.2% vs 44.6% NCT00913458
- 20.8% vs 12.5% NCT01313208
- 19.8% vs 4.8% NCT01313208
- 13.2% vs 4.8% NCT01313208
- 5.7% vs 3% NCT01313208
- 65.8% vs 60.3% NCT00848354
- 68.5% vs 62.7% NCT00848354
- 67.3% vs 53.2% NCT00848354
- 67.3% vs 58.7% NCT00848354
- 62.0% vs 23.2% NCT00848354
- 59.1% vs 27.5% NCT00848354
- 56.3% vs 24.6% NCT00848354
- 73.4% vs 60.8% NCT00848354
- 52.3% vs 21.1% NCT00848354
- 42.3% vs 16.9% NCT00848354
- 31.5% vs 8.4% NCT00848354
- 15.8% vs 2.9% NCT00848354
- 73.4% vs 61.7% NCT00848354
- 72.6% vs 59.2% NCT00848354
- 70.5% vs 65% NCT00848354
ACR70
- adalimumab-afzb (Abrilada)
- 36.4% vs 31.9%vs Adalimumab-EUNCT02480153
11 other results
- 38.5% vs 32.6% NCT02480153
- 36% vs 26.7% NCT02480153
- 33.9% vs 30.4% NCT02480153
- 29.6% vs 31% NCT02480153
- 31.1% vs 30.4% NCT02480153
- 21.5% vs 22% NCT02480153
- 16.5% vs 19% NCT02480153
- 12.5% vs 11.7% NCT02480153
- 8.1% vs 8.7% NCT02480153
- 3.7% vs 3.7% NCT02480153
- 0.7% vs 2% NCT02480153
- etanercept
- 36.3% vs 15.9%vs MethotrexateNCT00445770
64 other results
- 36.3% vs 18.2% NCT00445770
- 35.7% vs 14.8% NCT00445770
- 31.3% vs 11.9% NCT00445770
- 25.8% vs 11.9% NCT00445770
- 25.3% vs 13.1% NCT00445770
- 18.7% vs 9.7% NCT00445770
- 15.4% vs 9.7% NCT00445770
- 11% vs 2.8% NCT00445770
- 8.2% vs 0.6% NCT00445770
- 3.8% vs 0% NCT00445770
- 33.9% vs 15.9% NCT00445770
- 34.4% vs 18.2% NCT00445770
- 31.3% vs 14.8% NCT00445770
- 28.1% vs 11.9% NCT00445770
- 25.5% vs 11.9% NCT00445770
- 25% vs 13.1% NCT00445770
- 17.7% vs 9.7% NCT00445770
- 21.9% vs 9.7% NCT00445770
- 15.1% vs 2.8% NCT00445770
- 7.8% vs 0.6% NCT00445770
- 4.2% vs 0% NCT00445770
- 28% vs 9.6% NCT00565409
- 31% vs 10.2% NCT00565409
- 28.7% vs 17.6% NCT00565409
- 33% vs 10.2% NCT00565409
- 42% vs 33% NCT00565409
- 32% vs 10.7% NCT00565409
- 34% vs 10.7% NCT00565409
- 35.5% vs 11.2% NCT00565409
- 30.8% vs 9.6% NCT00565409
- 31.3% vs 10.2% NCT00565409
- 27.9% vs 17.6% NCT00565409
- 28.9% vs 10.2% NCT00565409
- 33.3% vs 33% NCT00565409
- 31.3% vs 10.7% NCT00565409
- 30.3% vs 10.7% NCT00565409
- 31.3% vs 11.2% NCT00565409
- 82.5% vs 80% NCT00913458
- 73% vs 56.9% NCT00913458
- 77.8% vs 36.9% NCT00913458
- 74.6% vs 38.5% NCT00913458
- 16% vs 12.5% NCT01313208
- 17% vs 10.6% NCT01313208
- 8.5% vs 9.6% NCT01313208
- 69.8% vs 38.5% NCT00913458
- 5.7% vs 1% NCT01313208
- 5.7% vs 0% NCT01313208
- 1.9% vs 0% NCT01313208
- 1.9% vs 0% NCT01313208
- 45% vs 32.5% NCT00848354
- 39.6% vs 34.1% NCT00848354
- 40.4% vs 30.2% NCT00848354
- 41.9% vs 34.1% NCT00848354
- 34.8% vs 11.3% NCT00848354
- 30.1% vs 10.6% NCT00848354
- 27.6% vs 9.2% NCT00848354
- 53.1% vs 38.3% NCT00848354
- 20.1% vs 4.2% NCT00848354
- 16.1% vs 3.5% NCT00848354
- 7.2% vs 2.1% NCT00848354
- 3.6% vs 0.7% NCT00848354
- 49.0% vs 36.7% NCT00848354
- 48.5% vs 35% NCT00848354
- 49.0% vs 40% NCT00848354
DAS28-CRP remission
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 54.5% vs 69.1%vs Standard COBRA-Slim InductionNCT03649061
1 other result
- 58.2% vs 43.6% NCT03649061
HAQ-DI, change
- adalimumab-afzb (Abrilada)
- -0.7 vs -0.7vs Adalimumab-EUNCT02480153
11 other results
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.7 vs -0.7 NCT02480153
- -0.6 vs -0.6 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.5 vs -0.5 NCT02480153
- -0.4 vs -0.5 NCT02480153
- -0.3 vs -0.4 NCT02480153
- -0.3 vs -0.3 NCT02480153
- etanercept
- -0.6 vs -0.3vs MethotrexateNCT00445770
31 other results
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.2 NCT00445770
- -0.4 vs -0.1 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.6 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.3 NCT00445770
- -0.5 vs -0.2 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.3 vs -0.1 NCT00445770
- -0.5 vs -0.4 NCT01313208
- -0.4 vs -0.4 NCT01313208
- -0.4 vs -0.3 NCT01313208
- -0.4 vs -0.2 NCT01313208
- -0.4 vs -0.2 NCT01313208
- -0.3 vs -0.2 NCT01313208
- -0.3 vs -0.1 NCT01313208
- -0.8 vs -0.5 NCT00848354
- 0.8 vs 0.7 NCT03649061
- 0.9 vs 0.7 NCT03649061
Modified Sharp score, change
- adalimumab-afzb (Abrilada)
- —Not reported
- etanercept
- 3.3 vs 9.8vs MethotrexateNCT00445770
11 other results
- 5.2 vs 9.8 NCT00445770
- 1.7 vs 5.1 NCT00445770
- 2.4 vs 5.1 NCT00445770
- 0 vs 0.5 NCT00913458
- 0 vs -1 NCT00858780
- 0 vs -1 NCT00858780
- 7 vs 7.3 NCT00259610
- 4.8 vs 7.3 NCT00259610
- 0.4 vs 1.4 NCT00848354
- 0.8 vs 0.7 NCT03649061
- 0.3 vs 0.5 NCT03649061
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. adalimumab-afzb (Abrilada): 14 of 16 rows · etanercept: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-afzb (Abrilada) | etanercept Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 88.4% (n=259) @ 52wk*a,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 229 Participants as posted | 69.3% (n=306) @ 52wk*50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 212 Participants as posted |
| ACR50 responder rate · % of participants No placebo or comparator arm | 68.3% (n=259) @ 52wk*a,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted | 66% (n=306) @ 52wk*50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 202 Participants as posted |
| ACR70 responder rate · % of participants No placebo or comparator arm | 39.8% (n=259) @ 52wk*a,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted | 57.5% (n=306) @ 52wk*50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 176 Participants as posted |
| DAS Remission responder rate · % of participants | 37.8% (n=283) vs 29.6% (n=135) Adalimumab-EU @ 52wk*a,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 107 Participants as posted | 95.2% (n=63) vs 92.3% (n=65) placebo @ 52wk*a,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 60 Participants as posted |
| DAS Remission responder rate · % of participants No placebo or comparator arm | 41.3% (n=259) @ 52wk*a,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 107 Participants as posted | 63.1% (n=306) @ 52wk*50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination · converted to % from 193 Participants as posted |
| DAS28-CRP absolute change · score | -2.8 vs -2.8 Adalimumab-EU score @ 36wkb NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | 0.18 vs 0.49 Methotrexate score @ 36wkd,b NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy show 1 more dose0.2 vs 0.49 Methotrexate score @ 36wk NCT02373813 · Phase 3 · registry result, not featured evidence · combination |
| DAS28-CRP absolute change · score No placebo or comparator arm | -3.2 score @ 78wkb,e,f NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -2.5 score @ 24wkb,e,f NCT02378506 · Phase 3 · registry result, not featured evidence |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.781 score @ 78wkb,e,f NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -0.5 score @ 24wkb,e,f NCT02378506 · Phase 3 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score | -37.5 vs -38.6 Adalimumab-EU score @ 52wka,b,e NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -3.91 vs -3.02 placebo score @ 52wka,b,e NCT01578850 · Phase 4 · registry result, not featured evidence 2 other source trials-3.04 vs -1.97 Methotrexate score @ 52wk10 mg NCT00445770 · Phase 3 · registry result, not featured evidence -2.91 vs -1.97 Methotrexate score @ 52wk25 mg NCT00445770 · Phase 3 · registry result, not featured evidence |
| Patient Global Assessment absolute change · score No placebo or comparator arm | -38.3 score @ 52wka,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -48.6 score @ 52wk50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination |
| Physician Global Assessment absolute change · score | -47.9 vs -48.4 Adalimumab-EU score @ 52wka,b,e NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -4.77 vs -3.74 placebo score @ 52wka,b,e NCT01578850 · Phase 4 · registry result, not featured evidence 2 other source trials-3.68 vs -2.72 Methotrexate score @ 52wk10 mg NCT00445770 · Phase 3 · registry result, not featured evidence -4.07 vs -2.72 Methotrexate score @ 52wk25 mg NCT00445770 · Phase 3 · registry result, not featured evidence |
| Physician Global Assessment absolute change · score No placebo or comparator arm | -48.9 score @ 52wka,b,c NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | -49.2 score @ 52wk50 mg QWa,b,c NCT00913458 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | —Period 1: PF-06410293g NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | —0.4 mg/kgh NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results62.5%Adult Participants NCT00357903 · Phase 3 · monotherapy 74.1%Pediatric Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Subjects NCT00357903 · Phase 3 · monotherapy —Total Adults NCT00357903 · Phase 3 · monotherapy 16.4% NCT03649061 · Phase 4 · registry result, not featured evidence · combination — NCT01578850 · Phase 4 · registry result, not featured evidence 4.7%Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 4.3%Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 29.9%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 49%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 36.6%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00858780 · Phase 4 · registry result, not featured evidence —25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 9.4%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 9.5% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 40.5%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 16.9%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 31.1% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 2% NCT00422227 · Phase 4 · registry result, not featured evidence 19.3%Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination —Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 31.3%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination — NCT02986139 · Phase 3 · registry result, not featured evidence 13.3% NCT02378506 · Phase 3 · registry result, not featured evidence 17%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 18.2%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 8%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 6.7%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 2.4%50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence 14.3% NCT00361634 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Period 1: PF-06410293g NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results—Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 — NCT04230213 · Phase 3 | —0.4 mg/kgh NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results15%Adult Participants NCT00357903 · Phase 3 · monotherapy 6.9%Pediatric Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Subjects NCT00357903 · Phase 3 · monotherapy —Total Adults NCT00357903 · Phase 3 · monotherapy — NCT03649061 · Phase 4 · registry result, not featured evidence · combination — NCT01578850 · Phase 4 · registry result, not featured evidence 1.9%Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 1.8%Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination —Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 5.6%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 9.2%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 6.5%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00858780 · Phase 4 · registry result, not featured evidence —25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 2%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination —25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 2.4% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 5.4%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 1.3%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 4.5% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT00422227 · Phase 4 · registry result, not featured evidence 9.9%Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy —Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination —Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 0.8%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination — NCT02986139 · Phase 3 · registry result, not featured evidence 7.4% NCT02378506 · Phase 3 · registry result, not featured evidence 10.4%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 7.8%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 5.8%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 4.1%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence —50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence — NCT00361634 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 4%Period 1: PF-06410293g NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more results1.4%Period 2: PF-06410293/PF-06410293 NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 3.5%Period 3: PF-06410293/PF-06410293/ NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.4% NCT04230213 · Phase 3 | 4%0.4 mg/kgh NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 44 more results—Adult Participants NCT00357903 · Phase 3 · monotherapy —Pediatric Participants NCT00357903 · Phase 3 · monotherapy 27.6%Pediatric Subjects NCT00357903 · Phase 3 · monotherapy 50.4%Total Adults NCT00357903 · Phase 3 · monotherapy 9.1% NCT03649061 · Phase 4 · registry result, not featured evidence · combination 0% NCT01578850 · Phase 4 · registry result, not featured evidence —Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 3.8%Etanercept-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence 2.9%Placebo-Etanercept NCT01313208 · Phase 4 · registry result, not featured evidence —Etanercept + Methotrexate NCT00848354 · Phase 4 · registry result, not featured evidence · combination 3.6%Etanercept + Methotrexate Phase 1 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 6.5%Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 4.6%Etanercept + Methotrexate Phase 2 NCT00848354 · Phase 4 · registry result, not featured evidence · combination 15.9%Etanercept + Methotrexate NCT00654368 · Phase 4 · registry result, not featured evidence · combination 11.2%Etanercept Alone NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 9.2%50 mg QW NCT00913458 · Phase 4 · registry result, not featured evidence · combination 4.8%E25 + MTX (Phase 2) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 0%E25+MTX (Phase 3) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 4.3%50 mg NCT00858780 · Phase 4 · registry result, not featured evidence 3.7%25 mg NCT00858780 · Phase 4 · registry result, not featured evidence 4.6%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 6.4%50 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 3.5%25 mg NCT00565409 · Phase 4 · registry result, not featured evidence · combination 4.8% NCT00443430 · Phase 4 · registry result, not featured evidence · combination 2.8%ETN Alone NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy 11.8%ETN+MTX NCT00688103 · Phase 4 · registry result, not featured evidence · combination 14.3% NCT00259610 · Phase 4 · registry result, not featured evidence · combination 3% NCT00422227 · Phase 4 · registry result, not featured evidence —Year 1 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 E+M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination —Year 1 M / Year 2 E+M NCT00195494 · Phase 4 · registry result, not featured evidence · combination 3%Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy 3.8%Double-Blind Treatment: Etanercept NCT02373813 · Phase 3 · registry result, not featured evidence · combination 3.9%Open Label Rescue: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 3.8%Open Label Run-In: Etanercept Plus NCT02373813 · Phase 3 · registry result, not featured evidence · combination 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence 4.8% NCT02378506 · Phase 3 · registry result, not featured evidence 6%25 mg NCT00445770 · Phase 3 · registry result, not featured evidence 4.2%10 mg NCT00445770 · Phase 3 · registry result, not featured evidence 5.5%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence 2.9%50 mg NCT00459706 · Phase 3 · registry result, not featured evidence —50 mg once weekly NCT00418717 · Phase 3 · registry result, not featured evidence 0% NCT00361634 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g viral upper respiratory tract infection 7.1% rheumatoid arthritis 1.7% nasopharyngitis 0% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 3 more resultsviral upper respiratory tract infection 5.3% rheumatoid arthritis 1.4% nasopharyngitis 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 nasopharyngitis 5% rheumatoid arthritis 4.7% viral upper respiratory tract infection 0.4% NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 | 0.4 mg/kgh upper respiratory tract infection 40% (placebo 15.4%) headache 20% (placebo 11.5%) gastroenteritis 12% (placebo 3.8%) NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 show 40 more resultsupper respiratory tract infection 62.1% headache 34.5% pharyngitis 22.4% NCT00357903 · Phase 3 · monotherapy upper respiratory tract infection 35.6% sinusitis 20.8% bronchitis 15.3% NCT00357903 · Phase 3 · monotherapy nausea 25.5% fatigue 23.6% hepatic function abnormal 16.4% NCT03649061 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 2.4% (placebo 5.1%) NCT01578850 · Phase 4 · registry result, not featured evidence injection site erythema 12.3% rheumatoid arthritis 11.3% headache 8.5% NCT01313208 · Phase 4 · registry result, not featured evidence headache 15.4% upper respiratory tract infection 12.5% nasopharyngitis 11.5% NCT01313208 · Phase 4 · registry result, not featured evidence bronchitis 6.4% influenza 5.3% nasopharyngitis 5% NCT00848354 · Phase 4 · registry result, not featured evidence · combination bronchitis 4.2% influenza 4.2% nasopharyngitis 4.2% NCT00848354 · Phase 4 · registry result, not featured evidence · combination bronchitis 7.1% nasopharyngitis 4.6% urinary tract infection 4.6% NCT00848354 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 17.8% nasopharyngitis 11.2% sinusitis 10.3% NCT00654368 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 13.3% nasopharyngitis 10.2% headache 9.2% NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy 50 mg QW nasopharyngitis 12.7% (placebo 4.6%) nausea 12.7% (placebo 0%) headache 6.5% (placebo 0%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% (placebo 4.6%) upper respiratory tract infection 6.3% (placebo 4.6%) rheumatoid arthritis 3.2% (placebo 9.2%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 18.9% (placebo 9.2%) nasopharyngitis 5.7% (placebo 4.6%) alanine aminotransferase increased 0% (placebo 0%) NCT00913458 · Phase 4 · registry result, not featured evidence · combination 50 mg nasopharyngitis 26.1% (placebo 8.7%) upper respiratory tract infection 26.1% (placebo 8.7%) back pain 13% (placebo 0%) NCT00858780 · Phase 4 · registry result, not featured evidence 25 mg nasopharyngitis 29.6% (placebo 8.7%) arthralgia 11.1% (placebo 0%) gastroenteritis 11.1% (placebo 0%) NCT00858780 · Phase 4 · registry result, not featured evidence 50 mg headache 6.1% (placebo 0%) nasopharyngitis 5.8% (placebo 5%) bronchitis 0% (placebo 3%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination 50 mg nasopharyngitis 8.9% (placebo 5%) bronchitis 5.9% (placebo 3%) pharyngitis 1.5% (placebo 5.5%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination 25 mg bronchitis 5.4% (placebo 3%) nasopharyngitis 5% (placebo 5%) pharyngitis 2.5% (placebo 5.5%) NCT00565409 · Phase 4 · registry result, not featured evidence · combination liver function test elevation 7.1% NCT00443430 · Phase 4 · registry result, not featured evidence · combination upper airway viral infection 40.8% rash 26.8% injection site reaction 22.5% NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy upper airway viral infection 43.4% injection site reaction 11.8% gastroentelitis 10.5% NCT00688103 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 53.7% (placebo 57.3%) joint pain 27% (placebo 22.4%) dermatalogic eruption 14.8% (placebo 14.5%) NCT00259610 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 13.7% alanine aminotransferase increased 5.6% aspartate aminotransferase increased 3.6% NCT00422227 · Phase 4 · registry result, not featured evidence administration site conditions 24.5% nausea 19.3% investigations 17.9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 44.1% injury, poisoning and procedural complications 13.5% nasopharyngitis 9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 42.3% injury, poisoning and procedural complications 11.7% nasopharyngitis 9% NCT00195494 · Phase 4 · registry result, not featured evidence · combination infections and infestations 36.7% injury, poisoning and procedural complications 12.2% nasopharyngitis 11.1% NCT00195494 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 7.1% bronchitis 3% upper respiratory tract infection 3% NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy bronchitis 7.5% rheumatoid arthritis 5.7% upper respiratory tract infection 1.9% NCT02373813 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 6.8% rheumatoid arthritis 1.9% bronchitis 0% NCT02373813 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 5.4% bronchitis 1.6% rheumatoid arthritis 0.8% NCT02373813 · Phase 3 · registry result, not featured evidence · combination hypoaesthesia 1.9% pain in extremity 1.9% cellulitis 0.9% NCT02986139 · Phase 3 · registry result, not featured evidence injection site erythema 10.7% nasopharyngitis 7% upper respiratory tract infection 7% NCT02378506 · Phase 3 · registry result, not featured evidence 25 mg nasopharyngitis 20.3% upper respiratory tract infection 11.5% pharyngitis 8.2% NCT00445770 · Phase 3 · registry result, not featured evidence 10 mg nasopharyngitis 23.4% upper respiratory tract infection 10.4% pharyngitis 9.4% NCT00445770 · Phase 3 · registry result, not featured evidence 50 mg injection site reaction 14.2% injection site erythema 7.7% nasopharyngitis 6.8% NCT00459706 · Phase 3 · registry result, not featured evidence 50 mg injection site reaction 17.6% injection site erythema 9.3% nasopharyngitis 8.3% NCT00459706 · Phase 3 · registry result, not featured evidence 50 mg once weekly infections and infestations 28.6% dizziness 7.1% headache 4.8% NCT00418717 · Phase 3 · registry result, not featured evidence dry skin 23.1% injection site reaction 23.1% cough 15.4% NCT00361634 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context differs: combination versus monotherapy.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eTreatment context has not been resolved for both arms.
- fAssessment timepoints differ: 24 weeks versus 78 weeks.
- gPopulation comparability has not been reviewed for 1 of these studies.
- hPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab-afzb (Abrilada)
show 11 more results
show 4 more results
show 11 more results
show 4 more results
show 11 more results
show 4 more results
+ 30 further endpoints in the CSV export.
etanercept
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 222 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-afzb (Abrilada)'s landscape · etanercept's landscape